Acumen Pharmaceuticals develops experimental antibody treatments for Alzheimer's disease. It last closed at $0.23 on Nov 17, up 6.53% on the day. ABOS last reported earnings on Mon, Oct 26, 2026. The average 12-month price target from 2 analysts is $1.00 (+334.6% from the last close), with a high of $1.00 and a low of $1.00.
Only 2 firms rated ABOS in the past 90 days, not enough for a consensus
Average 12-month target
$1.00
▲ 334.6% upside
Based on 2 analysts who set a price target on ABOS in the past 90 days. The average target is $1.00, with a high of $1.00 and a low of $1.00, compared with the last close of $0.23.
Low $1.00Avg $1.00High $1.00
Blue marker: last close $0.23
Highest target$1.00
Average target$1.00
Lowest target$1.00
Latest rating changes
BTIGMaintained
Nov 2Buy$1
CitigroupDowngrade
Oct 30Hold$5 → $1
CitigroupMaintained
Sep 15Buy$5
Date
Firm
Action
Rating
Price target
Nov 2
BTIG
Maintained
Buy
$1
Oct 30
Citigroup
Downgrade
Hold
$5 → $1
Sep 15
Citigroup
Maintained
Buy
$5
Loading…
Technical Analysis
ABOS · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 295% below its 20 day and 652% below its 50 day average. It is 934% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot at $0.22, and the nearest resistance the Pivot R1 at $0.24.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 65.2%/day
Key levels
$3.6052 week high+1465.2%
$2.38200 day average+934.8%
$2.17100 day average+843.5%
$1.7350 day average+652.2%
$0.9120 day average+295.7%
$0.25Swing high (Nov 10)+8.7%
$0.24Pivot R1+4.3%
$0.23Last close
$0.22Pivot−4.3%
$0.21Pivot S1−8.7%
$0.1952 week low−17.4%
$0.19Swing low (Nov 5)−17.4%
Indicators
RSI (14)
22.50
Oversold below 30
Oversold
MACD
-0.50
Below its signal line
Bearish
Stochastic
1.2
Near the bottom of its range
Oversold
ADX (14)
41.9
Strong downtrend
Williams %R
-98.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-51.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.8%
Change over 10 sessions
Bearish
ATR (14)
$0.15
Typical daily range, 65.2% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 199.2%/day
Key levels
$3.6052 week high+1465.2%
$2.38200 day average+934.8%
$2.17100 day average+843.5%
$1.7350 day average+652.2%
$0.9120 day average+295.7%
$0.25Swing high (Nov 10)+8.7%
$0.24Pivot R1+4.3%
$0.23Last close
$0.22Pivot−4.3%
$0.21Pivot S1−8.7%
$0.1952 week low−17.4%
$0.19Swing low (Nov 5)−17.4%
Indicators
RSI (14)
29.20
Oversold below 30
Oversold
MACD
-0.53
Below its signal line
Bearish
Stochastic
1.0
Near the bottom of its range
Oversold
ADX (14)
26.1
Trending down
Williams %R
-98.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-176.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−92.1%
Change over 10 sessions
Bearish
ATR (14)
$0.46
Typical daily range, 199.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ABOS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ABOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ABOS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ABOS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABOS is in one of them and how their past ABOS trades turned out.
Acumen Pharmaceuticals is a biopharmaceutical company based in Newton, Massachusetts, that is developing treatments for Alzheimer's disease. Its lead candidate, sabirnetug, is an antibody designed to target soluble amyloid-beta oligomers, which the company believes play a central role in the disease. Sabirnetug is in a Phase 2 trial for people with mild cognitive impairment or mild dementia due to Alzheimer's. The company is also developing a brain-delivery platform with a partner and does not yet have a product on the market.